British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 4, Issue.: 34 (01-10 December)
Use of DonnatalTM Elixir in the Treatment of Neonatal Abstinence Syndrome
Alyssa Brzenski1 and Mark Greenberg1* 1Department of Anesthesiology, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103-8770, USA.
Alyssa Brzenski1 and Mark Greenberg1*
1Department of Anesthesiology, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103-8770, USA.
(1) Dr. Oswin Grollmuss, Head of Department of Pediatric and Adult Resuscitation Congenital Heart of Centre, Chirurgical Marie Lannelongue, University Paris XI, France.
(2) Allegaert Karel, Belgium.
Complete Peer review History: http://www.sciencedomain.org/review-history/5539
We present the case of a 6-week-old male infant with Neonatal Abstinence Syndrome (NAS) in which DonnatalTM (phenobarbital, hyoscyamine, atropine, hyoscine) Elixir was used as an adjunct therapy. The infant was born to a mother taking 130mg of methadone per day since conception. Due to NAS, he was treated with a methadone taper and oral clonidine. Yet, despite the majority of symptoms being suppressed with these medications, he remained stricken with colicky pain, unresponsive to supplemental opioids. A trial of DonnatalTM resulted in relief of symptoms and completion of his opioid taper. We recommend DonnatalTM as part of the treatment plan for refractory abdominal symptoms in cases of NAS.
DonnatalTM; belladonna alkaloids; withdrawal; colic; neonatal abstinence syndrome; visceral abdominal pain.
Full Article - PDF Page 5446-5450
DOI : 10.9734/BJMMR/2014/12419Review History Comments